HF-158K1 by HighField Biopharmaceuticals for Prostate Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Prostate Cancer.

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement – Biotech Investments

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of

March 16, 2024

Exclusive: Biotech tools company raises $75M for protein manufacturing tech

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 16, 2024

New smartphone-based device can quickly identify infected wounds

It’s notoriously difficult for doctors to identify a wound that is becoming infected. Clinical signs and symptoms are imprecise and methods of identifying bacteria can

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.